What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Donna Niedzwiecki spends much of her time researching Internal medicine, Surgery, Colorectal cancer, Oncology and Chemotherapy.
Donna Niedzwiecki regularly links together related areas like Gastroenterology in her Internal medicine studies.
Her work deals with themes such as Microsatellite instability, Proportional hazards model, Radiology, Hazard ratio and Cohort, which intersect with Colorectal cancer.
Her Oncology study integrates concerns from other disciplines, such as Cetuximab, Oxaliplatin, FOLFOX, KRAS and Bevacizumab.
Her Chemotherapy study combines topics in areas such as Clinical endpoint, Topoisomerase, Survival analysis and Pharmacology.
Donna Niedzwiecki has researched Cancer in several fields, including Etoposide, Leukemia and Group B.
Her most cited work include:
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781 (950 citations)
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) (633 citations)
- Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (562 citations)
What are the main themes of her work throughout her whole career to date?
Donna Niedzwiecki mostly deals with Internal medicine, Oncology, Colorectal cancer, Surgery and Cancer.
Her study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Transplantation.
Her study in Oncology is interdisciplinary in nature, drawing from both Irinotecan, Oxaliplatin, FOLFOX, KRAS and Bevacizumab.
Her Colorectal cancer research is multidisciplinary, relying on both Prospective cohort study, Proportional hazards model, Adjuvant therapy and Cancer research.
Her Cancer study combines topics from a wide range of disciplines, such as Microsatellite instability, Leukemia, Immunology, Pathology and Group B.
Her work carried out in the field of Chemotherapy brings together such families of science as Rectum and Toxicity.
She most often published in these fields:
- Internal medicine (67.00%)
- Oncology (42.36%)
- Colorectal cancer (34.24%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (67.00%)
- Oncology (42.36%)
- Colorectal cancer (34.24%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Internal medicine, Oncology, Colorectal cancer, Cancer and Hazard ratio.
Donna Niedzwiecki regularly ties together related areas like Gastroenterology in her Internal medicine studies.
Her Oncology research includes elements of Gemcitabine, Chemotherapy and Capecitabine.
Her studies in Colorectal cancer integrate themes in fields like Cancer research, Chemotherapy regimen, Proportional hazards model and Cohort study.
She interconnects Acquired immune system, CD8, Immune system and Group B in the investigation of issues within Cancer.
Her Hazard ratio research integrates issues from Randomized controlled trial and Insulin.
Between 2017 and 2021, her most popular works were:
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (301 citations)
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (301 citations)
- Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome (84 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Colorectal cancer, Oncology, Hazard ratio and Cancer are her primary areas of study.
Her Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology.
Her Colorectal cancer research is multidisciplinary, incorporating perspectives in Receptor, Chemotherapy regimen, Allele and Cohort study.
The study incorporates disciplines such as Stage, Surgical resection, Predictive value of tests and Microsatellite instability in addition to Oncology.
Her Hazard ratio research focuses on FOLFOX and how it relates to Fluorouracil.
Her work in the fields of Cancer, such as Nab-paclitaxel, intersects with other areas such as High rate.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
